Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth
Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth
Abstract Preterm births are prevalent and a leading cause of neonatal death in the United States. Despite the availability of effective interventions, to date there is not a robust and widely applicable test to identify pregnancies at high risk for spontaneous preterm birth (sPTB). Previously, a sPTB predictor based on the ratio of two proteins, IBP4/SHBG, was validated as an accurate predictor of sPTB in the observational study Proteomic Assessment of Preterm Risk (PAPR). Here it is demonstrated that the same predictor threshold associated with 2-fold increased risk of sPTB, namely ?1.4, is also statistically significant for predicting elevated risk of sPTB in the observational study Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TreeToP).
Boniface J. Jay、Kearney Paul E.、Burchard Julja、Fox Angela C.、Fleischer Tracey C.、Dufford Max、Garite Thomas J.、Randolph Todd、Polpitiya Ashoka D.、Critchfield Greg C.
Sera Prognostics, Inc.Data Incites, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc.Sera Prognostics, Inc., independent consultantSera Prognostics, Inc.
医学研究方法妇产科学基础医学
Boniface J. Jay,Kearney Paul E.,Burchard Julja,Fox Angela C.,Fleischer Tracey C.,Dufford Max,Garite Thomas J.,Randolph Todd,Polpitiya Ashoka D.,Critchfield Greg C..Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth[EB/OL].(2025-03-28)[2025-08-03].https://www.medrxiv.org/content/10.1101/2021.01.23.21249902.点此复制
评论